iShares MSCI Germany (DAX) vs Natera Inc. Common Stock — how do they compare? iShares MSCI Germany (DAX) trades at $40.94 (market cap $1.53B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 37.3× iShares MSCI Germany (DAX)'s market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 55 Days and Natera Inc. Common Stock for 0 Days on average.
| EWG | NTRA | |
|---|---|---|
Market Cap | $1.53B | $57.03B |
Volume | 1,020,541 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $425.64 |
52-Week Low | $38.08 | $179.42 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $56.18B |
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.20 with a modest 0.59% daily gain, though technical indicators signal a bearish trend with moving averages showing 4 buy versus 9 sell signals. The stock faces resistance at $42 with support at $41. Recent European market focus highlights resilience amid ECB rate hikes and energy price pressures affecting regional equities.
Outlook remains cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on European economic stability, but risks include prolonged inflation and energy market volatility. Stock-specific fundamentals are unavailable, requiring deeper due diligence.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →